NCT04185610 (QiGong) is a NA clinical trial of Qi Gong in Chemotherapy-induced Peripheral Neuropathy, sponsored by Arash Asher, MD.

Who is sponsoring NCT04185610?

NCT04185610 is sponsored by Arash Asher, MD.

What drugs are being tested in NCT04185610?

Interventions in NCT04185610: Qi Gong.

What condition does NCT04185610 study?

NCT04185610 studies Chemotherapy-induced Peripheral Neuropathy, Cancer.

Is NCT04185610 still recruiting?

NCT04185610 is currently terminated. Last updated 29 September 2022.

Last reviewed 2022-09-29 · How we verify

NCT04185610: QiGong

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy

Terminated NA Last updated 29 September 2022

What this trial tests

NA trial testing Qi Gong in Chemotherapy-induced Peripheral Neuropathy in 6 participants. Terminated before completion.

Timeline

4 December 2019

Primary endpoint
17 March 2020

17 March 2020

Quick facts

Lead sponsor	Arash Asher, MD
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	6
Start date	4 December 2019
Primary completion	17 March 2020
Estimated completion	17 March 2020
Sites	1 location across United States

Drugs / interventions tested

Qi Gong

Conditions studied

Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
Cancer — all drugs for Cancer →

Sponsor

Arash Asher, MD

Who can join

18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study will include up to 25 patients with cancer experiencing chemotherapy-induced peripheral neuropathy. Patients enrolled in the study will participate in a 10-week QiGong for Chemotherapy-Induced Neuropathy program. Patients will be evaluated before and after their program participation. Within 2 weeks before the program start date, patients will be administered an objective neuropathy assessment by a physician or nurse, and will complete questionnaires assessing chemotherapy-induced peripheral neuropathy, perceived cognitive functioning, quality of life, and cancer-related symptoms. Patients will repeat these assessments at the end of the last QiGong class and will be asked to provide feedback on the QiGong program as a whole. Self-report questionnaires will also be repeated one week after the last class. Total duration of subject participation will be 11-13 weeks. Total duration of the study is expected to be approximately 9 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Qi Gong

Trials testing the same drug.

NCT02732470 — Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi) · NA · completed

Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy

Currently open trials in the same condition.

NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting

Other Arash Asher, MD trials

Trials by the same sponsor.

NCT05128838 — RISE (Reinvent, Integrate, Strengthen, Expand) Self-Management Program for Cancer Survivors: A Feasibility Study · EARLY_PHASE1 · completed
NCT04403802 — Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy · NA · completed
NCT03824132 — LOL: It's All Improv After Cancer!™ · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04185610 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arash Asher, MD
Last refreshed: 29 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04185610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing